Puma Biotechnology | PBYI - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Daiichi Sankyo JPY 249.96B 21.73B 2026-06
Exelixis USD 147.63M 8.03M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 351.73M 23.64M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Moderna USD 216M 43M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Takeda JPY 286.51B 5.48B 2026-06
TG Therapeutics USD 62.32M 10.82M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06